Cherry (C3RY) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
12 Aug, 2026Executive summary
Q1 2026 saw operational improvements and organizational simplification through Project Blossom, targeting sustainable profitability and EBITDA/EBIT breakeven by 2027.
Revenue declined 17.8% year-over-year to EUR 20.8 million, mainly due to weak demand in Gaming & Office Peripherals and strategic realignment.
Digital Health & Solutions (DH&S) segment delivered strong growth, with revenue more than tripling year-over-year, driven by regulatory mandates and delayed telematic infrastructure rollout in Germany.
Peripherals business is being repositioned for profitable growth, focusing on core input devices, asset-light operations, and a leaner, scalable model.
Major milestones include improved OPEX control, positive free cash flow, and management board changes to streamline operations.
Financial highlights
Group revenue for Q1 2026 was EUR 20.8 million, down 17.8% year-over-year due to one-off effects, weak demand, and FX headwinds.
Adjusted EBITDA improved to minus EUR 600,000 (margin -2.9%) from minus EUR 2 million (margin -8.0%) in Q1 2025, with margin up over 5 percentage points year-over-year.
Free cash flow was positive at EUR 1.1 million, about EUR 10 million better than last year, mainly from working capital management.
Gross margin increased to 46.7% from 43.7% year-over-year, reflecting better pricing and product mix.
Net loss narrowed to EUR 4.0 million from EUR 5.8 million year-over-year, driven by reduced operating costs and lower depreciation.
Outlook and guidance
No reliable full-year outlook provided due to ongoing M&A process and incomplete 2025 financials; more details expected next quarter.
Project Blossom targets EBITDA/EBIT breakeven in 2027, with targeted OPEX savings and revenue growth across office, gaming, and security segments.
DH&S segment is well-positioned in the German e-health market, with recurring revenue and strong regulatory-driven demand.
Peripherals business transformation aims for a leaner, scalable model with higher margins and cash generation.
Latest events from Cherry
- Gross margin rose to 45.1% and adjusted EBITDA loss narrowed to EUR 4 million amid transformation.C3RY
Q2 2026 - 2025 revenue fell 15% to €94.3m, with restructuring, cost cuts, and segment review ongoing.C3RY
Q4 2025 - 2024 guidance targets €140m–€150m revenue and a 7–8% EBITDA margin, signaling a strong turnaround.C3RY
Investor presentation - Revenue and EBITDA fell short, triggering cost cuts and a revised €120m 2024 outlook.C3RY
Investor presentation - Streamlined for margin-driven growth, with €120M 2024 revenue forecast and €3.5M cost savings.C3RY
Investor presentation - Restructuring, M&A, and operational streamlining target a return to growth and financial stability.C3RY
Investor presentation - Revenue dropped 25% in H1 2025, with negative EBITDA and liquidity boosted by asset sales.C3RY
Q2 2025 - Q3 2024 results missed expectations, triggering restructuring and a cut in full-year guidance.C3RY
Q3 2024 TU - Digital Health & Solutions drove revenue growth, but margin pressure and restructuring widened net loss.C3RY
Q2 2024